Back to top
more

Aptose Biosciences (APTO)

(Delayed Data from NSDQ)

$1.20 USD

1.20
30,913

+0.01 (0.84%)

Updated May 3, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (80 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Kodiak Sciences (KOD) Q2 Earnings Lag, Eye Candidate in Focus

by Zacks Equity Research

Kodiak Sciences (KOD) reports wider-than-expected loss for the second quarter of 2021. Pipeline development remains in focus for the company.

    Aptose Biosciences (APTO) Moves to Buy: Rationale Behind the Upgrade

    by Zacks Equity Research

    Aptose Biosciences (APTO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    by Zacks Equity Research

    Aptose Biosciences (APTO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Is a Beat in Store for Zoetis (ZTS) This Earnings Season?

    by Zacks Equity Research

    Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases second-quarter 2021 results.

    Sorrento (SRNE) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    Sorrento (SRNE) will provide updates on earnings and revenues when it releases second-quarter 2021 results.

    Vertex (VRTX) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    On Vertex's (VRTX) second-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and pipeline progress.

    CRISPR (CRSP) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    On CRISPR Therapeutics' (CRSP) Q2 earnings call, investors will look forward to the company's advancement with its lead gene-editing candidate CTX001.

      Will Pfizer (PFE) Beat Expectations This Earnings Season?

      by Zacks Equity Research

      Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, and Inlyta, and revenues from COVID-19 vaccine are likely to have driven sales in the second quarter.

      Is the Options Market Predicting a Spike in Aptose (APTO) Stock?

      by Zacks Equity Research

      Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

      Aerpio (ARPO) Seeks Strategic Options for Pipeline Programs

      by Zacks Equity Research

      Aerpio (ARPO) unveils strategic alternatives after it announced top-line results from a phase II study of razuprotafib in glaucoma patients in December.

      Novo Nordisk (NVO) Files for Ozempic's Label Expansion in EU

      by Zacks Equity Research

      Novo Nordisk (NVO) files for a label expansion of Ozempic in the EU to include a new dose of 2.0 mg.

      Aptose Biosciences (APTO) Sees Hammer Chart Pattern: Time to Buy?

      by Zacks Equity Research

      Aptose Biosciences (APTO) has been struggling lately, but the selling pressure may be coming to an end soon.

      Novartis' (NVS) Entresto Gets FDA Panel Nod for Expanded Use

      by Zacks Equity Research

      Novartis (NVS) gets positive review from the FDA Advisory Committee to support the use of Entresto in the treatment of patients with heart failure with preserved ejection fraction.

      Athenex (ATNX) Gets FDA Approval for Skin Treatment Klisyri

      by Zacks Equity Research

      Athenex (ATNX) wins the FDA nod for Klisyri as a topical treatment of actinic keratosis on the face or scalp. The drug will be launched in the first quarter of 2021 in the United States.

      Roche (RHHBY) Gets FDA Nod for Shorter Infusion Time of Ocrevus

      by Zacks Equity Research

      The FDA approves Roche's (RHHBY) Ocrevus for two-hour infusion time, dosed twice-yearly to patients with relapsing or primary progressive MS.

      Acceleron's (XLRN) PAH Candidate Gets Orphan Designation in EU

      by Zacks Equity Research

      Acceleron's (XLRN) investigational therapy sotatercept receives an Orphan designation in Europe for the treatment of patients with pulmonary arterial hypertension. Shares up.

      Seagen (SGEN) Gets Positive CHMP Opinion for Breast Cancer Drug

      by Zacks Equity Research

      Seagen (SGEN) gets a positive opinion from the CHMP, recommending the approval of Tukysa for the treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer.

      Bristol Myers (BMY) Gets Positive CHMP Opinion for Inrebic

      by Zacks Equity Research

      Bristol Myers (BMY) gets positive CHMP opinion for Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.

      ADMA Biologics (ADMA) in Focus: Stock Moves 6.6% Higher

      by Zacks Equity Research

      ADMA Biologics (ADMA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

      FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda

      by Zacks Equity Research

      Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

      Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies

      by Zacks Equity Research

      Bayer (BAYRY) inks a deal with Atara to sell the latter's to -generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.

      Implied Volatility Surging for Aptose (APTO) Stock Options

      by Zacks Equity Research

      Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.

      Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study

      by Zacks Equity Research

      Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

      CytoDyn (CYDY) Enrolls First Patient in NASH Study on Leronlimab

      by Zacks Equity Research

      CytoDyn (CYDY) enrolls first patient in the phase II study evaluating leronlimab for the treatment of nonalcoholic steatohepatitis.

      Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study

      by Zacks Equity Research

      Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.